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University,	 the	University	 of	 Florida,	 and	Virginia	 Tech.	Her	 research	 focus	 in	graduate	
school	was	on	nutrition	and	exercise	effects	on	bone	development	in	horses.	She	has	held	
several	 positions	 in	 both	 academia	 and	 industry,	 including	working	 for	 the	 Ohio	 State	
University,	Buckeye	Nutrition,	and	Virginia	Tech	before	joining	Murray	State	University.	In	
addition	to	her	other	duties,	Dr.	Porr	supports	the	horse	industry	through	presentations	at	





My	 decision	 to	 return	 to	 Murray	 State	 for	 my	 master’s	 was	 simple	 thanks	 to	 my	
positive		undergraduate	experience.	During	that	time,	I	was	given	the	opportunity	to	
participate	in		research	and	attend	my	first	conference.	After	some	time	spent	in	the	
industry	 training		 Icelandic	 Horses	 and	 providing	 riding	 lessons,	 I	 discovered	 that	
teaching	was	a	career		path	I	wanted	to	pursue.	This	research	project	began	with	the	
investigation	 of		 foundational	 knowledge	 of	 CBD	 in	 the	 horse	 and	worked	 towards	
evaluating	its	impact		on	both	behavior	and	movement.	Not	only	have	I	gained	valuable	
knowledge	and		understanding	of	the	subject	matter	and	research	process,	but	also	I	
have	 thoroughly		enjoyed	experiencing	 the	collaboration	and	teamwork	essential	 to	

























for	 a	 complete	blood	 chemistry	 (CBC)	evaluation.	 Statistics	were	 completed	on	 serum	chemistry	
using	 PROC	 MIXED	 procedure	 of	 SAS.	 Serum	 chemistry	 and	 CBC	 results	 were	 within	 normal	




















	 Cannabis	 sativa	 L.	 has	 piqued	 the	
interest	 of	 both	 medical-	 and	 industry-
based	 research	 (Callaway,	 2004;	 Zuardi,	
2006;	 Russo,	 2007;	 Hartsel	 et	 al.,	 2016).	
The	recent	passing	of	the	2014	and	2018	
Farm	Bill	 Acts	 served	 to	 legally	 separate	
hemp	 from	 marijuana,	 requiring	 the	
concentration	 of	 the	 psychoactive	






receptors	 (Freund	 et	 al.,	 2003).	 While	
research	 has	 been	 directed	 towards	 CBD	
as	 a	 physical	 and	 behavioral	 therapeutic	
agent	 in	 mice	 (Malfait	 et	 al.,	 2000),	 rats	
(Hammell	 et	 al.,	 2016;	 Philpott	 et	 al.,	




All	 vertebrates	 have	 an	
endocannabinoid	 system	 that	 serves	 as	
the	 master	 regulator	 of	 bodily	
homeostasis	 (McPartland	et	 al.,	 2005;	De	
Laurentiis,	 2014;	 Sallaberry	 and	 Astern,	
2018;	Hartsel	et	al.,	2019).	Dependent	on	
the	interaction	of	cannabinoids,	regulatory	
enzymes,	 and	 receptors,	 the	 system	
functions	 through	 a	 negative	 feedback	
loop	(Pertwee,	2006;	Mackie,	2008).	There	
are	 three	 primary	 classifications	 of	
cannabinoids,	 including	
endocannabinoids,	 phytocannabinoids,	
and	 synthetics	 (Scuderi	 et	 al.,	 2009).	
Endocannabinoids	 naturally	 exist	 in	 the	
body,	phytocannabinoids	derive	 from	the	
plant	C.	sativa,	and	synthetic	cannabinoids	
are	 purified	 isolates	 with	 increased	
potency.	 Both	 phytocannabinoids	 and	
synthetic	 cannabinoids	 mimic	 natural	
endocannabinoid	 effects	 and	may	 impact	
receptor	 interaction	 (Landa	 et	 al.,	 2016).	
Two	primary	receptors	 identified	 include	
cannabinoid	 receptor	 1	 (CB1)	 and	
cannabinoid	 receptor	 2	 (CB2).	 Primarily,	
CB1	 receptors	 are	 located	 within	 the	
central	 nervous	 system,	 while	 CB2	
receptors	are	associated	with	the	immune	
system	 and	 cytokine	 release	 (Howlett	 et	
al.,	 2002;	 Pertwee,	 2006).	 Existing	
research	 supports	 this	 system’s	 role	 in	 a	
wide	range	of	central	nervous	system	and	
endocrine	functions.	Specific	roles	include	
immune	 system	 and	 inflammatory	
responses,	 influence	 on	 heart	 rate	 and	
blood	 pressure,	 inhibition	 of	 tumor	 cell	
growth,	 nociception	 modulation,	 and	





Proposed	 medicinal	 benefits	 of	
CBD	 range	 from	 physical	 healing	 to	
behavioral	 modification.	 Specific	
conditions	marketed	 for	 humans	 include	
epilepsy,	 multiple	 sclerosis,	 anxiety,	
rheumatoid	 arthritis,	 inflammation,	 and	
anxiety	 disorders.	 Relative	 to	 horses	
specifically,	 behavioral	 modification	
seems	to	be	a	popular	 focus	 for	CBD	use.	
Despite	 lay	 claims	 from	 owners	 and	
supplement	 companies,	 species	 specific	
pharmacological	 understanding	 of	 CBD	
and	 other	 cannabinoids	 is	 relatively	 low.	
Factors	 such	 as	 receptor	 location	 and	
absorption	 rates	 within	 certain	 species	
may	 vary,	 and	 could	 potentially	 increase	







Detection	 techniques	 are	 still	
advancing,	 particularly	 in	 reference	 to	
cannabinoid	detection	in	equine	serum.	A	
pilot	 study	 demonstrated	 that	 both	
pelleted	 and	 oil-based	 CBD	 products	
appear	 to	 be	 bioavailable	 to	 the	 horse;	
however,	 detection	 concentrations	 at	 the	
current	 dosage	 recommendations	 are	
relatively	low	and	difficult	to	detect	(Jones	
et	al.,	2020).	One	of	the	current	methods	of	
serum	 cannabinoid	 detection	 is	 through	
the	 use	 of	 liquid	 chromatography-mass	
spectrometry	 (LC/MS)	 (Gamble	 et	 al.,	
2018;	Davis,	2019;	Deabold	et	al.,	2019).	In	
this	 method,	 physical	 separation	 must	
occur	 first	 through	 dissolving	 the	 CBD-
containing	 serum	 sample	 in	 a	 solution,	
followed	 by	mass	 analysis.	 In	 LC-MS/MS	
instruments,	 there	 is	 a	 second	 mass	
spectrometry	detector	attached.	Though	a	
standard	 for	 testing	 has	 not	 yet	 been	
implemented	 due	 to	 lack	 of	 regulation,	
some	 of	 the	 most	 sensitive	 HPLC-LC/MS	
methods	 are	 reading	 serum	 cannabinoid	
concentrations	 down	 to	 a	 0.05	 ng/mL	
lower	 limit	 of	 quantification	 (LLOQ).	
However,	 LLOQ	 for	 research	 reports	 has	
typically	 been	 above	 1	 ng/mL	 (Davis,	
2019;	 Deabold	 et	 al.,	 2019).	 Product	
analysis	 may	 occur	 through	 both	 LC-
MS/MS	 and	 high	 performance	 liquid	
chromatography	 diode-array	 detectors	
(HPLC-DAD).	 Following	 physical	
separation,	 DAD	 allows	 researchers	 to	
examine	 samples	 for	 organic	 compounds	




MS/MS	 is	 considered	 to	 contain	 greater	







have	 been	 completed	 in	 murine	 models,	
dogs,	 and	 humans	 (Malfait	 et	 al.,	 2000;	
Lodzki	et	al.,	2003;	Blake	et	al.,	2006;	Jeong	
et	al.,	2014;	Hammell	et	al.,	2016;	Devinsky	
et	 al.,	 2018).	 Current	 literature	
demonstrates	 potential	 for	 various	
administration	methods	of	CBD	to	contain	
medicinal	 capabilities	 within	 controlled	
research	 settings	 (Lodzki	 et	 al.,	 2003;	
Blake	 et	 al.,	 2006;	 Scuderi	 et	 al.,	 2009;	
Devinsky	et	al.,	2018).	However,	a	product	
under	 consideration	 for	 pharmaceutical	
qualities	must	undergo	species	and	dose-





Determination	 of	 potential	 positive	 and	
negative	 consequences	 of	 CBD	medicinal	
use,	 if	 any,	 is	 a	 necessary	 step	 for	
consideration	 as	 a	 form	 of	 treatment.	
Research	is	particularly	needed	in	regards	




completed	 in	 other	 species	 typically	




some	 species,	 such	 as	 cats,	 have	
demonstrated	a	Tmax	as	 long	as	4	hours	
(Deabold	 et	 al.,	 2019).	 A	 deeper	
understanding	 of	 pharmacokinetic	
measures	 such	 as	 this	 could	 assist	 in	
providing	 the	proper	dosing	 amount	 and	
frequency.	 A	 case	 study	 on	 a	 horse	
suffering	 from	 neuropathic	 pain	
demonstrated	 alleviation	 of	 pain	with	 an	
oral	dose	of	0.5	mg/kg	bodyweight	 twice	






maintenance	 dose.	 Dosing	 was	 based	
loosely	 on	 human	 medicine.	 Though	 it	
turned	 out	 to	 be	 safe,	 the	 author	
reaffirmed	the	need	for	research	to	better	
understand	 drug	 interactions	 and	 dose	
guidelines.	While	negative	effects	were	not	
observed	 in	 this	 study,	 blood	 sample	
results	were	not	 reported.	Data	 on	other	
species	 treated	 with	 CBD	 has	
demonstrated	 a	 rise	 in	 certain	 enzymes,	
such	 as	 alkaline	 phosphatase	 (ALP)	
(Gamble	et	al.,	2018;	Deabold	et	al.,	2019).	
	
Despite	 the	 lack	 of	 supporting	
research,	 the	 use	 of	 CBD	 products	 in	
humans	 and	 animals	 has	 grown	 rapidly.	
The	primary	 intent	of	 this	project	was	 to	
evaluate	 the	 properties	 of	 oral	 CBD	
products	 in	 horses	 to	 increase	
understanding	 of	 product	 availability,	
pharmacokinetics	of	CBD	in	the	horse,	and	
the	 physiological	 results	 of	 a	 single	
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Eighteen	 Quarter	 Horse	 geldings	
from	 a	 university	 riding	 program	 were	
selected.	 Weekly	 exercise	 demand	 was	
categorized	 as	 low	 to	 moderate	 for	 all	
horses	 (1	 h/wk,	 3	 h/wk,	 respectively;	
National	Research	Council,	2007).	Average	
age	 was	 15±4.2	 yrs,	 and	 horses	 had	 an	
average	 weight	 of	 555±40.9	 kg.	 Groups	
were	balanced	by	 typical	housing,	stalled	
(n=7)	versus	pasture	kept	horses	(n=11),	
and	 age.	 Young	 horses	 were	 considered	
≤14	 yrs	 (n=10)	 and	 aged	 ≥15	 yrs	 (n=8).	
Subsequently,	 subjects	 were	 randomly	
divided	into	one	of	three	treatment	groups	
(n=6):	50	mg	 (TXT1),	100	mg	 (TXT2),	or	
250	 mg	 (TXT3).	 Manufacturer	 dosing	
recommendations	 were	 25-50	 mg	 1-2	
times	daily.	In	a	pilot	trial,	the	50	mg	dose	
did	 not	 reach	 sufficient	 serum	
concentrations	 at	 2	 h	 to	 guarantee	
consistent	 detection	 for	 pharmacokinetic	
analysis.	 A	 high	 dose	 of	 250	 mg	 was	
derived	 from	 a	 case	 study	 that	
demonstrated	efficacy	and	safety	for	pain	
management	 in	 a	 horse	 with	 extended	
treatment	 (Ellis	 and	 Contino,	 2019).	
Horses	were	stalled	for	the	duration	of	the	
study	 (total	 time	 approximately	 30	 hr),	
and	 fed	 their	 standard	 rations	 of	
bermudagrass	 hay	 and	 concentrate	 with	
free	choice	water.	Subjects	known	to	have	
negative	 behavioral	 reactions	 associated	
with	 being	 stalled	 were	 avoided.	
Concentrate	included	a	once	daily	feeding	
of	 Southern	 States®	 (Southern	 States,	
Cadiz,	KY)	HSS	Reliance	12%	protein,	6%	
fat	 bulk	 horse	 pellets	 (n=15)	 or	 Kalm’N	
EZ®	 (Tribute	 Equine	 Nutrition®,	 Upper	
Sandusky,	 OH),	 (n=3).	 Rations	 included	
the	 following,	 depending	 on	 the	
individual's	 needs:	 4	 quarts	 (n=15),	 2	
quarts	 (n=1),	 or	 6	 quarts	 (n=2).	 Horses	
were	 handwalked	 regularly,	 during	 stall	
cleanings.	 One	 test	 subject	 was	 on	 a	
Vitamin	 E	 supplement.	 Intravenous	
jugular	 catheters	 were	 placed	 by	 a	
veterinarian	 within	 2	 hr	 of	 stall	
confinement.	Following	study	conclusion,	
catheters	were	removed	and	horses	were	








Blood	 collection	 for	 each	 horse	
consisted	 of	 four	 10	 ml	 serum	
Vacutainers®	 for	 cannabinoid	 analysis	
and	serum	chemistry,	as	well	as	one	10	ml	
EDTA	 Vacutainer®	 for	 a	 complete	 blood	
count	 (CBC)	 (Vacutainer®,	 Becton,	
Dickinson	 and	 Company,	 Franklin	 Lakes,	
NJ).	 The	 first	 blood	 collection	 (pre-




collection	 (0	 h),	 all	 horses	 were	
administered	 a	 single	 dose	 of	 full-
spectrum,	ground	and	pelleted	CBD	 from	
industrial	 hemp	 (Equine	 Veterinary	
Services	 Pharm,	 Paducah,	 KY,	 USA)	 in	
accordance	 with	 their	 treatment	 group.	
Other	ingredients	mixed	into	the	pelleted	
product	 included	 the	 flavoring	 agent,	
Apple	 Ade	 (Nutriad,	 Inc,	 Hampshire,	 IL,	
USA)	 and	 mold	 inhibitor,	 Myo	 CURB®	
(Kemin	Industries,	Inc.©,	Verona,	MO,	US).	
Dosages	 were	 based	 on	 manufacturer	
recommendations	 and	 research	 available	
on	 other	 species.	 Subsequent	 catheter	
drawn	cannabinoid	samples	were	taken	at	







3500	 RPM	 (LWS-Combo-V24	 Centrifuge	
LW	Scientific,	Atlanta,	GA).	A	minimum	of	
5	 cc	 of	 serum	 was	 pipetted	 into	 5	 mL	
Eppendorf	 storage	 tubes	 (Eppendorf	
Tubes®	 0030119452,	 online-
shop.eppendorf.us,	 USA)	 and	 chilled	 in	 a	
refrigerator	 at	 4.4º	 C	 until	 serum	
chemistry	 analysis.	 Comparative	 lab	
analysis	 through	 accredited	 labs	 was	
incorporated	 to	 validate	 blood	
concentrations	 and	 testing	 procedures.	
Serum	 chemistry	 and	 CBC	 samples	 were	




C	 freezer	 until	 shipment	 for	 analysis.	
Pharmacokinetics	were	evaluated	in	order	
to	 determine	 the	 effect	 of	 a	 single	 dose.	
Serum	cannabinoid	potency	was	analyzed	
by	 the	 Pharmacology	 Shared	 Resource	
(University	of	Colorado	Cancer	Center)	at	




Pump	 SL	 HPLC	 system	was	 coupled	 to	 a	
3200	 Q-TRAP	 triple	 quadruple	 mass	






	 Statistical	 analysis	 for	 serum	
chemistry	 was	 completed	 through	 PROC	
MIXED	 Procedure	 of	 SAS	 (SAS,	 Cary,	 NC,	
USA).	 The	 experimental	 unit	 was	 horse,	
with	 each	 serving	 as	 its	 own	 control.	
Results	were	analyzed	under	the	effects	of	
treatment	 and	 time.	Dependent	variables	
included	 blood	 urea	 nitrogen	 (BUN),	
albumin,	 creatinine,	 and	 alkaline	
phosphatase	(ALP)	to	monitor	kidney	and	






No	 negative	 behaviors	 or	 effects	












has	 been	 documented	 in	 other	 species	
(Table	1;	Gamble	et	al.,	2018;	Deabold	et	
al.,	 2019).	 Only	 horses	 administered	 the	
250	 mg	 dose	 showed	 serum	
concentrations	at	or	above	the	lower	limit	
of	quantification	(LLOQ)	of	1	ng/ml,	with	
the	 exception	 of	 one	 horse	 from	 the	 100	
mg	treatment	group.	One	out	of	six	horses	
on	 the	 250	mg	 dose	 did	 not	 reach	 LLOQ	
detection	 levels.	 This	 horse	 consumed	
only	120	mg	of	the	250	mg	dose.	Despite	a	
portion	 of	 the	 horses	 (n=6)	 reaching	 a	
quantifiable	CBD	serum	concentration,	all	
levels	 remained	 quite	 low	 (Table	 1).	
Additionally,	dosing	was	not	adjusted	per	
bodyweight,	 though	 horses	 were	 of	
comparable	 breed	 type	 and	 contained	
limited	 variability	 in	 weight	
(mean=555±40.9	 kg).	 Maintaining	
consistent	CBD	presence	above	LLOQ	via	
more	 efficient	 and	 higher	 dosing	 by	
bodyweight	 could	 assist	 in	 achieving	 a	
heightened	 understanding	 of	 CBD	
pharmacokinetics.	 Results	 from	 CBC	
analysis	 returned	 within	 normal	
parameters.		
	




Data	 for	 some	 species,	 including	
horses,	 suggests	 Tmax	 could	 extend	
beyond	 2	 hr	 (Davis,	 2019).	 One	
explanation	for	this	discrepancy	could	be	
that	 the	 current	 study	 had	 gaps	 within	
blood	collection	times	where	a	maximum	
could	have	occurred	without	opportunity	
for	 detection.	 Although	 concentrations	
dropped	at	the	subsequent	4	hr	collection,	
it	 is	 not	 possible	 to	 know	 if	 those	
concentrations	 continued	 to	 rise	because	
samples	were	not	collected	between	2	and	
4	hr	post	treatment.	It	is	also	possible	that	
the	 CBD	 bioavailability	 depends	 on	 the	
method	of	administration	(Figure	1).	 In	a	
trial	 using	 oral	 CBD	 oil	 (Davis,	 2019),	




quickly	 in	 this	 trial,	 the	 actual	maximum	
concentration	 (Cmax)	 geometric	 mean	
observed	in	Davis’	study	was	higher	(27.2	
ng/mL	 versus	 3.04	 ng/mL,	 respectively).	
Therefore,	 although	 the	 amount	
administered	was	 less,	 and	 it	 potentially	
took	 longer	 to	 absorb,	 a	 greater	
percentage	of	 the	product	was	ultimately	
absorbed.	This	is	likely	attributable	to	the	
first	 pass	 effect	 at	 the	 liver	 and	 highly	
variable	 bioavailability	 observed	 with	





Figure	 1.	 Comparison	 of	 the	 geometric	 mean	 for	
CBD	concentrations	detected	in	the	blood	and	time	
that	 the	 maximum	 concentration	 was	 reached	










Though	 serum	 chemistry	 results	
indicated	 all	 concentrations	 were	 within	
reference	 ranges,	 significant	 changes	
within	 those	 ranges	 were	 observed	
(Figure	 2,	 Figure	 3,	 Figure	 4).	 A	


























Observations	 pertaining	 to	 the	
impact	of	time	on	enzyme	concentrations	
are	 summarized	 in	 Table	 3.	 Though	
changes	 were	 seen	 based	 on	 treatment	
and	 time	 for	 some	measures,	 each	 horse	
ultimately	remained	well	within	reference	
ranges.	A	 low	albumin	concentration	and	
high	 ALP	 could	 indicate	 poor	 liver	
function.	 Observations	 from	 this	 study	
contained	 limited	 concentration	 shifts,	
with	 all	 being	 within	 expected	 reference	
ranges.	 Typically,	 signs	 of	 kidney	
dysfunction	 would	 demonstrate	 a	
concurrent	 rise	 of	 BUN	 and	 creatinine.	
Within	 the	 documented	 ranges,	 BUN	




treatments	 that	 stimulated	 concentration	
fluctuation,	 such	 changes	 did	 not	 reach	
concentrations	 of	 concern.	 There	 can	 be	
alternative	 factors	 that	 produce	
concentration	 changes,	 such	 as	 high	
protein	 diets	 or	 dehydration.	 Given	 the	
subjects	of	this	study	were	maintained	on	
bermudagrass	hay	with	free	choice	water,	





investigation.	 Ideally,	 all	 horses	 on	 the	





CBD	 uptake,	 not	 nutritional	 value	 or	




differences	 to	 CBD	 alone.	 Ultimately,	 the	
single	treatment	of	each	dose	represented	
in	this	study	appeared	to	produce	minimal	
changes	 in	 blood	 chemistry	
concentrations.	 However,	 as	 slight	
variations	 were	 observed,	 it	 would	 be	
appropriate	 to	 monitor	 such	 parameters	
with	extended	CBD	treatment.	
	







Figure	 5.	 Serum	 concentrations	 of	 blood	 urea	





	 Ultimately,	 the	 results	 suggest	
relative	 safety	 of	 dosing	 horses	 with	 a	
single	treatment	of	50	mg,	100	mg,	or	250	
mg	 of	 an	 oral	 pelleted	 CBD	 product.	
Though	 slight	 shifts	 in	 blood	 parameters	
occurred,	 each	 remained	 within	 normal	
reference	 ranges.	 From	 the	 given	
observations,	 horses	 appear	 relatively	
consistent	with	other	species	in	the	time	of	
concentration	 maximum	 in	 the	 blood.	
Primarily,	the	only	horses	reaching	above	
standard	LLOQ	were	in	the	250	mg	group,	
and	 those	 readings	 were	 still	 fairly	 low.	
Therefore,	 there	 is	 the	 potential	 that	
future	 pharmacokinetic	 trials	 will	 either	
require	 higher	 dose	 rates	 for	 consistent	
CBD	 detection,	 or	 need	 to	 seek	 more	
readily	 absorbed	 forms.	 While	 existing	
literature	 contains	 a	 base	 for	 canines	
(Gamble	et	al.,	2018),	humans	(Wade	et	al.,	
2004),	 felines	 (Deabold	et	 al.,	 2019),	 and	
murine	models	 (Malfait	et	al.,	2000),	 this	
project	 provided	 a	 foundation	 to	 expand	
upon	concerning	the	relative	safety	of	CBD	
and	dosing	 recommendations	 specifically	
in	 the	 horse.	 Future	 research	 should	
attempt	to	fill	the	time	gaps	of	this	project	
to	 more	 accurately	 represent	 the	
pharmacological	 nature	 of	 CBD	 in	 the	
horse.		
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